Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Newsmax
NMAX
5
Palantir
PLTR
HK Stock MarketDetailed Quotes
01875 TOT BIOPHARM-B
- 2.020
- +0.080+4.12%
Not Open Apr 1 16:08 CST
1.56BMarket Cap41.22P/E (TTM)
2.040High1.950Low189.60KVolume1.970Open1.940Pre Close378.07KTurnover0.03%Turnover Ratio41.22P/E (Static)772.79MShares2.79052wk High1.98P/B1.56BFloat Cap1.48052wk Low--Dividend TTM772.79MShs Float6.430Historical High--Dividend LFY4.64%Amplitude0.800Historical Low1.994Avg Price400Lot Size--Div YieldTTM--Div Yield LFY
TOT BIOPHARM-B Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 40.70%1.1B | 49.27%809.02M | 58.69%520.6M | 67.79%222.54M | 76.54%780.63M | 77.25%541.98M | 80.24%328.06M | 65.28%132.63M | 479.34%442.18M | 744.11%305.78M |
| Operating income | 40.70%1.1B | 58.69%520.6M | 76.54%780.63M | 80.24%328.06M | 479.34%442.18M | |||||
| Cost of sales | -52.87%-315.9M | ---- | -84.08%-143.7M | ---- | -188.76%-206.64M | ---- | -232.48%-78.06M | ---- | -46.49%-71.56M | ---- |
| Operating expenses | -52.87%-315.9M | -84.08%-143.7M | -188.76%-206.64M | -232.48%-78.06M | -46.49%-71.56M | |||||
| Gross profit | 36.32%782.43M | 50.76%376.91M | 54.87%573.99M | 57.69%250M | 1,248.97%370.62M | |||||
| Selling expenses | -37.57%-606.71M | ---- | -40.08%-276.48M | ---- | -116.23%-441.02M | ---- | -181.60%-197.38M | ---- | -792.62%-203.95M | ---- |
| Administrative expenses | -19.13%-81.38M | ---- | -3.22%-32.11M | ---- | -9.14%-68.31M | ---- | -21.04%-31.1M | ---- | -11.10%-62.59M | ---- |
| Research and development expenses | 23.66%-79.31M | ---- | 7.82%-46.06M | ---- | 31.28%-103.89M | ---- | 28.89%-49.97M | ---- | 29.59%-151.17M | ---- |
| Impairment and provision | 169.72%8.01M | ---- | 1,868.96%9.45M | ---- | -1,823.12%-11.48M | ---- | 152.00%480K | ---- | ---597K | ---- |
| -Other impairment is provision | 169.72%8.01M | ---- | 1,868.96%9.45M | ---- | -1,823.12%-11.48M | ---- | 152.00%480K | ---- | ---597K | ---- |
| Special items of operating profit | 3.18%18.22M | ---- | -88.46%1.55M | ---- | 104.92%17.65M | ---- | 798.05%13.39M | ---- | 28.39%8.62M | ---- |
| Operating profit | 224.79%41.25M | 328.17%33.26M | 15.40%-33.06M | -109.79%-14.58M | 84.95%-39.08M | |||||
| Financing income | 13.75%3.38M | ---- | 70.74%2.18M | ---- | 31.30%2.97M | ---- | 207.95%1.28M | ---- | 133.75%2.27M | ---- |
| Financing cost | -90.92%-9.88M | ---- | -71.65%-3.88M | ---- | 21.61%-5.18M | ---- | 33.85%-2.26M | ---- | -167.50%-6.6M | ---- |
| Share of profit from joint venture company | ---- | ---- | ---- | ---- | 62.39%-2.5M | ---- | 106.88%397K | ---- | -38,917.65%-6.63M | ---- |
| Earning before tax | 192.06%34.76M | 308.15%31.56M | 24.56%-37.76M | 3.57%-15.16M | 80.84%-50.05M | |||||
| Tax | ---- | ---- | ---- | ---- | ---1K | ---- | ---1K | ---- | ---- | ---- |
| After-tax profit from continuing operations | 192.05%34.76M | 308.13%31.56M | 24.56%-37.76M | 3.57%-15.16M | 80.84%-50.05M | |||||
| Earning after tax | 192.05%34.76M | 209.30%35.4M | 308.13%31.56M | 145.24%7.41M | 24.56%-37.76M | 22.28%-32.39M | 3.57%-15.16M | -247.46%-16.38M | 80.84%-50.05M | 76.57%-41.68M |
| Minority profit | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---130K | ---- |
| Profit attributable to shareholders | 192.05%34.76M | 209.30%35.4M | 308.13%31.56M | 145.24%7.41M | 24.36%-37.76M | 20.10%-32.39M | 3.57%-15.16M | -247.46%-16.38M | 80.89%-49.92M | 77.21%-40.54M |
| Basic earnings per share | 200.00%0.05 | 300.00%0.04 | 37.50%-0.05 | 33.33%-0.02 | 82.61%-0.08 | |||||
| Diluted earnings per share | 200.00%0.05 | 300.00%0.04 | 37.50%-0.05 | 33.33%-0.02 | 82.61%-0.08 | |||||
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- |
| Auditor | -- | -- | -- | -- | PricewaterhouseCoopers | -- | -- | -- | PricewaterhouseCoopers | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.